COVID-19 Boost As Pharma ROI Hits Heights Not Seen For Seven Years, Finds Deloitte
Expected return on investment for pharma firms jumped sharply to 7% in 2021, driven largely by COVID-19 R&D but even when the pandemic's impact was stripped out, there was an increase in core R&D productivity compared with 2020, a new report from Deloitte has found. The average cost of developing a drug also declined from 2020 to 2021.
You may also be interested in...
The decrease in overall R&D productivity continues – a trend that started in 2018. It would be too easy to attribute this fall in R&D productivity to COVID-19 alone.
Nine prominent drug candidates are awaiting an FDA approval decision in the next few months. With the help of Biomedtracker's Early 2022 Outlook Report, we take a look at the potential launches likely to shake up the market from HIV to wet AMD.
The French major has committed up to £5m for non-profit Protas, which aims to facilitate large clinical studies at a fraction of the usual price and form more pharmaceutical collaborations down the line.